XEN1720

XEN1720 is a potent and selective small molecule inhibitor of the voltage-gated sodium channel NaV1.7, developed by Xenon Pharmaceuticals. NaV1.7 is highly expressed in peripheral sensory neurons and plays a critical role in the generation and conduction of pain signals; mutations in the SCN9A gene (which encodes NaV1.7) are linked to various human pain disorders. XEN1720 is designed to provide targeted analgesia by blocking these channels, potentially offering a non-opioid alternative for pain management with reduced central nervous system side effects. The drug is currently in Phase 1 clinical development, where its safety, tolerability, and pharmacokinetics are being evaluated.